Transitioning From Inpatient to Outpatient Therapy in Patients with In-Hospital Hyperglycemia

References

• . Bode B, Amin A. Incretin-based therapies: review of the outpatient literature with implications for use in the hospital and after discharge. Hosp Pract (Minneap). 2009;37(1):7–21
   PubMedGoogle Scholar
• . Umpierrez GE, Isaacs SD, Bazargan N, You X, Thaler LM, Kitabchi AE. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab. 2002;87(3):978–982
   PubMed Web of Science ®Google Scholar
• . American College of Physicians. ACP Diabetes Care Guide: A Team-Based Practice Manual and Self-Assessment Program. Philadelphia, PA: American College of Physicians; 2007
   Google Scholar
• . Moghissi ES. Addressing hyperglycemia from hospital admission to discharge. Curr Med Res Opin. 2010;26(3):589–598
   PubMed Web of Science ®Google Scholar
• . Moghissi ES. Reexamining the evidence for inpatient glucose control: new recommendations for glycemic targets. Am J Health Syst Pharm. 2010;67(16 suppl 8):S3–S8
   PubMed Web of Science ®Google Scholar
• . Hassan E. Hyperglycemia management in the hospital setting. Am J Health Syst Pharm. 2007;64(10 suppl 6):S9–S14
   PubMedGoogle Scholar
• . Leite SA, Locatelli SB, Niece SP, Oliveira AR, Tockus D, Tosin T. Impact of hyperglycemia on morbidity and mortality, length of hospitalization and rates of re-hospitalization in a general hospital setting in Brazil. Diabetol Metab Syndr. 2010;2:49
   PubMed Web of Science ®Google Scholar
• . Bartnik M, Malmberg K, Norhammar A, Tenerz A, Ohrvik J, Rydén L. Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction. Eur Heart J. 2004;25(22):1990–1997
   PubMed Web of Science ®Google Scholar
• . Moghissi ES, Korytkowski MT, Dinardo M, ; American Association of Clinical Endocrinologists; American Diabetes Association. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care. 2009;32(6):1119–1131
   PubMed Web of Science ®Google Scholar
• . Moghissi ES, Korytkowski MT, Dinardo M, ; American Association of Clinical Endocrinologists; American Diabetes Association. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Endocr Pract. 2009;15(4):353–369
   PubMed Web of Science ®Google Scholar
• . American Diabetes Association. Standards of medical care in diabetes—2011. Diabetes Care. 2011;34( suppl 1):S11–S61
   PubMed Web of Science ®Google Scholar
• . Clement S. Management of diabetes and hyperglycemia in the hospital. Presented at: Society of Hospital Medicine Annual Meeting; May 25, 2007; Dallas, TX
   Google Scholar
• . Greci LS, Kailasam M, Malkani S, . Utility of HbA(1c) levels for diabetes case finding in hospitalized patients with hyperglycemia. Diabetes Care. 2003;26(4):1064–1068
   PubMed Web of Science ®Google Scholar
• . ; International Expert CommitteeNathan DM. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009;32(7):1327–1334
   PubMed Web of Science ®Google Scholar
• . Magaji V, Johnson JM. Inpatient management of hyperglycemia and diabetes. Clin Diabetes. 2011;29(1):3–9
   Google Scholar
• . Rudd C, Smith J. Discharge planning. Nurs Stand. 2002;17(5):33–37
   PubMedGoogle Scholar
• . The Commonwealth Fund. Harris interactive survey. 2008 Commonwealth Fund international health policy survey of sicker adults. http://www.commonwealthfund.org/Content/Surveys/2008/2008-Commonwealth-Fund-International-Health-Policy-Survey-of-Sicker-Adults.aspx. Accessed September 26, 2011
   Google Scholar
• . Wheeler K, Crawford R, McAdams D, Robinson R, Dunbar VG, Cook CB. Inpatient to outpatient transfer of diabetes care: perceptions of barriers to postdischarge followup in urban African American patients. Ethn Dis. 2007;17(2):238–243
   PubMed Web of Science ®Google Scholar
• . Kimmel B, Sullivan MM, Rushakoff RJ. Survey on transition from inpatient to outpatient for patients on insulin: what really goes on at home? Endocr Pract. 2010;16(5):785–791
   PubMed Web of Science ®Google Scholar
• . Wesorick D, O'Malley C, Rushakoff R, Larsen K, Magee M. Management of diabetes and hyperglycemia in the hospital: a practical guide to subcutaneous insulin use in the non-critically ill, adult patient. J Hosp Med. 2008;3( 5 suppl):17–28
   PubMed Web of Science ®Google Scholar
• . Nettles AT. Patient education in the hospital. Diabetes Spectr. 2005;18(1):44–48
   Google Scholar
• . ClinicalTrials.gov. Bridging the Gap by Transitional Care. http://clinicaltrials.gov/ct2/show/NCT01330121. Accessed October 4, 2011
   Google Scholar
• . ClinicalTrials.gov. Effect of Inpatient Diabetes Management on Outpatient Glycemic Control. http://clinicaltrials.gov/ct2/show/NCT00869362. Accessed September 26, 2011
   Google Scholar
• . Nathan DM, Buse JB, Davidson MB, ; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193–203
   PubMed Web of Science ®Google Scholar
• . Rodbard HW, Jellinger PS, Davidson JA, . Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15(6):540–559
   PubMed Web of Science ®Google Scholar
• . Hoogwerf BJ. Postoperative management of the diabetic patient. Med Clin North Am. 2001;85(5):1213–1228
   PubMed Web of Science ®Google Scholar
• . Madsbad S, Krarup T, Deacon CF, Holst JJ. Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials. Curr Opin Clin Nutr Metab Care. 2008;11(4):491–499
   PubMed Web of Science ®Google Scholar
• . Campbell RK. Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus. Clin Ther. 2011;33(5):511–527
   PubMed Web of Science ®Google Scholar
• . Joslin Diabetes Center and Joslin Clinic. Clinical guideline for pharmacological management of type 2 diabetes. http://www.joslin.org/bin_from_cms/Pharma_guideline_11._10.pdf. Published January 9, 2009. Updated November 2010. Accessed October 4, 2011
   Google Scholar
• . Tentolouris N, Voulgari C, Katsilambros N. A review of nateglinide in the management of patients with type 2 diabetes. Vasc Health Risk Manag. 2007;3(6):797–807
   PubMedGoogle Scholar
• . Sambol NC, Chiang J, O'Conner M, . Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus. J Clin Pharmacol. 1996;36(11):1012–1021
   PubMed Web of Science ®Google Scholar
• . O'Malley CW, Emanuele M, Halasyamani L, Amin AN; Society of Hospital Medicine Glycemic Control Task Force. Bridge over troubled waters: safe and effective transitions of the inpatient with hyperglycemia. J Hosp Med. 2008;3( 5 suppl):55–65
   PubMed Web of Science ®Google Scholar
• . Fowler MJ. Diabetes Treatment, Part 2: Oral agents for glycemic management. Clin Diabetes. 2007;25:131–134
   Google Scholar
• . Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010;(4):CD002967
   Google Scholar
• . Glucophage [package insert]. Princeton, NJ: Bristol-Myers Squibb Co; 2010
   Google Scholar
• . Warren RE, Strachan MW, Wild S, McKnight JA. Introducing estimated glomerular filtration rate (eGFR) into clinical practice in the UK: implications for the use of metformin. Diabet Med. 2007;24(5):494–497
   PubMed Web of Science ®Google Scholar
• . Viljoen A, Sinclair A. Safety and efficacy of rosiglitazone in the elderly diabetic patient. Vasc Health Risk Manag. 2009;5(1):389–395
   PubMedGoogle Scholar
• . US Food and Drug Administration. FDA briefing document. Division of Metabolism and Endocrine Products and Office of Surveillance and Epidemiology: Joint meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee. http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4308b1-02-fda-backgrounder.pdf. Published July 30, 2007. Accessed September 26, 2011
   Google Scholar
• . Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457–2471
   PubMed Web of Science ®Google Scholar
• . Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med. 2010;170(14):1191–1201
   PubMed Web of Science ®Google Scholar
• . Douglas IJ, Evans SJ, Pocock S, Smeeth L. The risk of fractures associated with thiazolidinediones: a self-controlled case-series study. PLoS Med. 2009;6(9):e1000154
   PubMed Web of Science ®Google Scholar
• . Lecka-Czernik B. Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis. Curr Osteoporos Rep. 2010;8(4):178–184
   PubMedGoogle Scholar
• . Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik B. Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology. 2004;145(1):401–406
   PubMed Web of Science ®Google Scholar
• . Lazarenko OP, Rzonca SO, Hogue WR, Swain FL, Suva LJ, Lecka-Czernik B. Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology. 2007;148(6):2669–2680
   PubMed Web of Science ®Google Scholar
• . Precose [package insert]. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc; 2011
   Google Scholar
• . Shyangdan DS, Royle PL, Clar C, Sharma P, Waugh NR. Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis. BMC Endocr Disord. 2010;10(1):20
   PubMedGoogle Scholar
• . Aroda VR, Ratner R. The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review. Diabetes Metab Res Rev. 2011;27(6):528–542
   PubMed Web of Science ®Google Scholar
• . Victoza [package insert]. Princeton, NJ: Novo Nordisk Inc; 2011
   Google Scholar
• . Byetta [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc; 2010
   Google Scholar
• . Anderson SL, Trujillo JM. Association of pancreatitis with glucagon-like peptide-1 agonist use. Ann Pharmacother. 2010;44(5):904–909
   PubMed Web of Science ®Google Scholar
• . Januvia [package insert]. Whitehouse Station, NJ: Merck & Co, Inc; 2010
   Google Scholar
• . Moghissi ES. Insulin strategies for managing inpatient and outpatient hyperglycemia and diabetes. Mt Sinai J Med. 2008;75(6):558–566
   PubMedGoogle Scholar
• . Lavernia F. Treating hyperglycemia and diabetes with insulin therapy: transition from inpatient to outpatient care. Medscape J Med. 2008;10(9):216
   PubMedGoogle Scholar
• . Braithwaite SS. The transition from insulin infusions to long-term diabetes therapy: the argument for insulin analogs. Semin Thorac Cardiovasc Surg. 2006;18(4):366–378
   PubMedGoogle Scholar
• . Clement S, Braithwaite SS, Magee MF, ; American Diabetes Association Diabetes in Hospitals Writing Committee. Management of diabetes and hyperglycemia in hospitals. Diabetes Care. 2004;27(2):553–591
   PubMed Web of Science ®Google Scholar
• . Bode BW, Braithwaite SS, Steed RD, Davidson PC. Intravenous insulin infusion therapy: indications, methods, and transition to subcutaneous insulin therapy. Endocr Pract. 2004;10( suppl 2):71–80
   PubMedGoogle Scholar
• . Vilsbøll T, Rosenstock J, Yki-Järvinen H, . Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2010;12(2):167–177
   PubMed Web of Science ®Google Scholar